Murano Trial: Sustained Disease Survival In Cll Following Venetoclax Plus Rituximab

MURANO trial: Sustained disease survival in CLL following venetoclax plus rituximab

MURANO: five-year follow-up on venetoclax plus rituximab for CLL

VJHemOnc – Video Journal of Hematology & HemOnc

MURANO trial: Venetoclax-rituximab shows sustained benefit in relapsed/refractory chronic lympho...

Venetoclax + Rituximab in Relapsed CLL

Venetoclax + rituximab for R/R CLL: 7-year results of the MURANO trial

VJHemOnc – Video Journal of Hematology & HemOnc

Long-Term Follow-Up Results for MURANO Trial in CLL

Targeted Oncology

Update from MURANO trial: venetoclax-rituximab leads to slower clonal growth rate in CLL

VJHemOnc – Video Journal of Hematology & HemOnc

MURANO Trial Update in R/R CLL

Lisaftoclax ramp-up combined with acalabrutinib or rituximab in patients with CLL/SLL

VJHemOnc – Video Journal of Hematology & HemOnc

Venetoclax plus rituximab for patients with relapsed / refractory CLL

The MURANO study in CLL: 5 years on

VJHemOnc – Video Journal of Hematology & HemOnc

Reviewing Key Points from the Phase III MURANO Trial in CLL

Targeted Oncology

Efficacy of subsequent therapies for CLL patients treated in the MURANO trial

VJHemOnc – Video Journal of Hematology & HemOnc

Venetoclax Plus Rituximab in Relapsed/Refractory CLL

Targeted Oncology

MURANO: venetoclax + rituximab in BIRC3-mutated R/R CLL

VJHemOnc – Video Journal of Hematology & HemOnc

Follow-Up Shows Venetoclax Plus Rituximab has Long-Term Efficacy in CLL

Targeted Oncology

Venetoclax/Rituximab Combo for Chronic Lymphocytic Leukemia Shows Reduced Disease Progression

MURANO Trial and Time-Limited Therapies

Targeted Oncology

MURANO trial: revolutionizing the standard of care for relapsed CLL patients

VJHemOnc – Video Journal of Hematology & HemOnc

Continued Five Year Benefit of Venetoclax Plus Rituxamab To Treat Chronic Lymphocytic Leukemia